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Background-—Infective endocarditis (IE) after transcatheter pulmonary valve implantation (TPVI) in dysfunctioning right ventricular
outflow tract conduits has evoked growing concerns. We aimed to investigate the incidence and the natural history of IE after TPVI
with the Melody valve through a systematic review of published data.
Methods and Results-—PubMed, EMBASE, and Web of Science databases were systematically searched for articles published
until March 2017, reporting on IE after TPVI with the Melody valve. Nine studies (including 851 patients and 2060 patient-years
of follow-up) were included in the analysis of the incidence of IE. The cumulative incidence of IE ranged from 3.2% to 25.0%,
whereas the annualized incidence rate ranged from 1.3% to 9.1% per patient-year. The median (interquartile range) time from
TPVI to the onset of IE was 18.0 (9.0–30.4) months (range, 1.0–72.0 months). The most common findings were positive blood
culture (93%), fever (89%), and new, significant, and/or progressive right ventricular outflow tract obstruction (79%); vegetations
were detectable on echocardiography in only 34% of cases. Of 69 patients with IE after TPVI, 6 (8.7%) died and 35 (52%)
underwent surgical and/or transcatheter reintervention. Death or reintervention was more common in patients with new/
significant right ventricular outflow tract obstruction (69% versus 33%; P=0.042) and in patients with non-streptococcal IE (73%
versus 30%; P=0.001).
Conclusions-—The incidence of IE after implantation of a Melody valve is significant, at least over the first 3 years after TPVI, and
varies considerably between the studies. Although surgical/percutaneous reintervention is a common consequence, some patients
can be managed medically, especially those with streptococcal infection and no right ventricular outflow tract obstruction. ( J Am
Heart Assoc. 2018;7:e008163. DOI: 10.1161/JAHA.117.008163.)
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O ne decade after Bonhoeffer et al
1 demonstrated the
feasibility of transcatheter pulmonary valve implanta-
tion (TPVI) in a right ventricular outflow tract (RVOT) conduit,
the US Food and Drug Administration approved the Melody
valve (a modified version of the original device of Bonhoeffer
et al,1 manufactured by Medtronic Inc, Minneapolis, MN)2 in
2010.
TPVI was subsequently shown to provide satisfactory
hemodynamic and clinical outcomes and a low rate of primary
valve dysfunction, especially with the marked reduction in the
rates of stent fracture after the wide adoption of routine
prestenting.3,4 However, valve dysfunction secondary to
infective endocarditis (IE) is increasingly recognized as a
threat to valve function and patients’ outcomes3,5 after TPVI.
This risk of IE should be kept in mind when considering the
expansion of the indications of TPVI to patients with native
RVOT and small/large pulmonary conduits,6 and as a valve-in-
valve treatment.7
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The incidence rate of Melody valve IE varies considerably
among the studies and is, reportedly, higher than the rate of
pulmonary homograft IE.5,8 Beyond the incidence rate, many
other basic aspects of this disease entity remain obscure,
including microbiologic features, presentation, and outcomes.
We aimed at investigating the incidence and natural history
of IE after Melody valve implantation through a systematic
review and pooled analysis of published data.
Methods
Because all results are derived from published data, the study
materials will not be made available. The search method will
be made available to other researchers for purposes of
reproducing the results.
Literature Search
An electronic search in PubMed, EMBASE, and Web of
Science databases for studies published until March 2017
was conducted to identify studies reporting on the incidence
and/or the natural history of IE in patients treated with a
Melody valve in the pulmonary/RVOT position. The details of
the PubMed search items are shown in Data S1. A thorough
review of the reference lists of retrieved studies as well as
relevant review articles and editorials was conducted for the
sake of completeness.
Eligibility Criteria of Studies and Data Extraction
The analysis consisted of 2 parts (the search strategy is
shown as PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analyses) flowchart9 in Figure S1):
1. The study-level nonpooled analysis of the incidence rate of
IE: For inclusion in this analysis, the studies were required
to: (1) include ≥20 consecutive patients; (2) involve an
average follow-up of at least 12 months after TPVI; and
(3) be published in peer-reviewed literature (conference
abstracts were excluded, conforming to Cochrane guide-
lines). As shown in Figure S1, 329 studies were initially
identified, of which 248 were excluded after title/abstract
review. Of the remaining 56 studies, 33 did not meet the
inclusion criteria (nonconsecutive series, n=13; short
follow-up, n=11; mixed cohort with other devices/nonpul-
monary position, n=2; and congress abstracts without
published details, n=7). Inclusion criteria were fulfilled by
23 studies, of which 14 were excluded because of
overlapping population. Nine studies (including 851
patients) were eventually included in this analysis.
2. The patient-level pooled analysis: The individual-patient
characteristics were extracted from studies reporting
detailed individual patients’ data (individual case reports/-
case series). Extracted data included baseline patient
characteristics, TPVI periprocedural data, and details of IE,
including time of onset, presentation, microbiologic stud-
ies, management, and outcome. A total of 22 studies
(comprising 69 case reports) were included in this
analysis. Special attention was exercised to avoid inclusion
of duplicate cases (the same case reported in >1
publication).
Definitions
Overall, IE was defined as any documented blood-borne
infection treated with intravenous antimicrobial therapy for at
least 2 weeks, presumed to be related to Melody valve in the
absence of an alternative focus of infection. Endocarditis
was reported according to the authors’ judgment or using the
modified Duke criteria.10,11 Definite TPV-related IE was
confirmed by the presence of vegetation(s) seen on the
Melody valve leaflets, stent, or adjacent RVOT conduit wall, as
documented by transthoracic/transesophageal/intracardiac
echocardiography, positron emission tomography (PET), sur-
gical explant examination, or autopsy. IE episodes occurring
within 1 year after TPVI were defined as “early IE.”12
New/progressive RVOT obstruction was defined as a
≥15 mm Hg increase in RVOT pressure gradient and/or
worsening of stenosis severity to moderate-severe on the
first echo-Doppler study after IE onset compared with
the latest study before IE. New/worsening pulmonary
Clinical Perspective
What Is New?
• The risk of infective endocarditis after implantation of the
Melody valve is significant, extending at least over the first
3 years after the procedure.
• The diagnosis is challenging, and the modified Duke criteria
have a modest diagnostic yield in this setting.
• Approximately 52% of patients require reintervention, either
surgically or percutaneously.
• The outcome is favorable when streptococci are the
causative organism and the right ventricular outflow tract
is not obstructed.
What Are the Clinical Implications?
• More attention should be paid to prevent and early detect
infective endocarditis in patients who receive Melody valve
implantation.
• Documentation of valvular involvement on echocardiogra-
phy is challenging, and failure to visualize vegetations
should not exclude the diagnosis of infective endocarditis
when the clinical suspicion is high.
• The causative organism and the pressure gradient across
the valve can be used for risk stratification of the patients.
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 2
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regurgitation was defined as pulmonary regurgitation that
progressed from mild or less to moderate-severe pulmonary
regurgitation on the first echo-Doppler study after IE onset
compared with the latest study before IE. Death attributable
to IE was defined as cardiac death during the same hospital
admission for IE.
Statistical Analysis
The systematic review was performed according to the Meta-
Analysis of Observational Studies in Epidemiology (Research-
Checklist) guidelines.13 Continuous variables are expressed
as meanSD or as median and interquartile range, as
appropriate. Categorical variables are presented as frequen-
cies and percentages. Linear correlation between the rate of
IE in the individual studies and the sample size/length of
follow up/years of enrollment was assessed using the
nonparametric Spearman’s correlation coefficient. Binary
logistic regression analysis was used to study the predictors
of IE-related death/reintervention, and the odds ratio and its
95% confidence interval (CI) were presented. Independent
variables were included in the final multivariable model if
associated with death/reintervention in univariable analysis
(P<0.10).
Statistical analysis was performed with SPSS 23 (IBM,
Armonk, NY). All probability values were 2 tailed, and P<0.05
was considered significant.
Results
Incidence of Melody Valve IE
A total of 9 studies14–22 were included in the analysis of
the incidence of IE after TPVI using the Melody valve. The
characteristics of the studies are summarized in Table 1. The
publication year was 2008 to 2017, and the reported cases
received TPVI from 2000 to 2015. A total of 851 patients
received Melody valve in the pulmonary/RVOT position,
mostly (89%) after prestenting. The median follow-up was
31 (range, 20–59) months, and a total of 2060 patient-years
of follow-up were included.
The cumulative incidence of IE varied between the studies
(range, 3.2%–25.0%), as did the annualized incidence rate
(range, 1.3%–9.1% per patient-year). In studies applying the
modified Duke criteria (n=4 studies16,19,21,22), the cumulative
incidence of IE ranged from 7.5% to 25.0%, and the annualized
incidence rate ranged from 3.7% to 6.3%. Both cumulative and
annualized incidences of IE were higher in studies with lower
numbers of patients (Figure 1A and 1B14–22). On the other
hand, the incidence was not influenced by the follow-up
duration (Figure 2A and 2B14–22). Figure 3 shows a summary
of the time period of patient enrollment in each study and the
respective cumulative (Figure 3A14–22) and annualized inci-
dence rate of IE (Figure 3B14–22), both trending to be higher in
later than in earlier studies.
Individual-Patient Characteristics of Melody Valve
Endocarditis Cases
In total, 69 detailed case reports of patients who developed
Melody valve IE were identified.17–38 The characteristics of
these patients are summarized in Table 2.
Patients had a mean age of 2211 (range, 4–56) years,
and they were predominantly men (84%). Most had a
pulmonary homograft (55%) or a bioprosthetic valve/valved
conduit (38%) implanted in the setting of correction of
tetralogy of Fallot (50%), aortic stenosis treated by a Ross
procedure (18%), truncus arteriosus (15%), or transposition of
the great arteries (10%).
Interval After TPVI
The median time from TPVI to onset of IE was 18.0 (in-
terquartile range, 9.0–30.4; range, 1.0–72.0) months. As
shown in Figure 4, 32% of cases occurred within 1 year after
TPVI, 27% occurred in the second year, 18% occurred in the
third year, and 23% occurred beyond 3 years after the
procedure.
Precipitating Factors
An identifiable portal for IE was reported in 25 cases. An
unprotected dental procedure/orthodontic/oral trauma was
reported in 9 of the 25 cases (36%). Other portals included
the following: an infected wound (n=3), cat scratches and
bites/veterinary medical practice (n=2), paranasal sinusitis
(2), cardiac catheterization (n=2), gastroenteritis (n=1), pneu-
monia (n=1), cystitis (n=1), dermatophytosis complex (n=1),
nail biting and bad hygiene (n=1), hemodialysis (n=1), and
tattooing (n=1).
Clinical Presentation
Fever was the most common presenting symptom (89%),
whereas vegetations were visualized by echocardiography in
only 34%. New, significant, and/or progressive RVOT
obstruction occurred in 79% of cases, and the pressure
gradient increase averaged 178 mm Hg. New significant
pulmonary regurgitation was documented in 2 cases
(Table 2). Other presentations of IE included right ventric-
ular failure (n=5), severe sepsis (n=5), septic pulmonary
embolism (n=5), gastrointestinal tract symptoms (n=4),
glomerulonephritis (n=1), and macrophage activation syn-
drome (n=1).
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 3
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Figure 1. Scatter plots of the cumulative (A) and annualized (B) incidence rate of infective endocarditis (IE)
plotted against the sample size (number of patients) of the individual studies14–22 (Spearman correlation
coefficient=0.80 and 0.73, P=0.010 and P=0.025, respectively).
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 5
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Figure 2. Scatter plots of the cumulative (A) and annualized (B) incidence rate of infective endocarditis (IE)
plotted against the follow-up duration (in months) of the individual studies14–22 (Spearman correlation
coefficient=0.16 and 0.27, P>0.05 for both). Dot size is proportionate to the sample size (number of patients)
of each study.
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Figure 3. Scatter plots of the cumulative (A) and annualized (B) incidence rate of infective endocarditis (IE)
plotted against the time period of patient enrollment of the individual studies14–22 (Spearman correlation
coefficient=0.81 and 0.57, P=0.008 and P=0.11, respectively). Dots correspond to the middle of the
enrollment time interval for each study, and dot size is proportionate to the sample size (number of patients)
of each study. The characteristics of the 9 studies are summarized in Table 1.
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Microbiologic Features
As shown in Table 2, most cases involved Gram-positive cocci
(42% staphylococci and 30% streptococci). This microbiologic
profile was similar between early (47% staphylococci and 32%
streptococci) and late (46% staphylococci and 27% strepto-
cocci; P>0.05) IE. Bacterial culture was negative in 5 cases, of
which serologic features and/or polymerase chain reaction of
excised valve revealed Bartonella henselae in 3.
Treatment and Outcome
Six patients died (8.7%) in the course of IE, and 11 patients
required urgent intervention (percutaneous and/or surgical)
to relieve critical RVOT obstruction or to remove the infected
valve to control septicemia. Furthermore, 24 patients required
intervention (mostly to relieve RVOT obstruction), either
during the same hospital admission (n=10) or electively
thereafter at a median of 4 months after IE onset (n=14).
Overall, 39 reinterventions (31 surgical replacement, 3
percutaneous stenting, 3 balloon dilatation, and 2 Melody-
in-Melody implantation) were performed, whereas antibiotic
therapy (for 6.21.3 weeks) was sufficient for clinical
stabilization without the need for any intervention in 23
patients (34%). Clinical outcome was not reported in 1 patient,
and the mode of treatment was not specified in 5 patients.
In total, 59.7% of the patients either died (n=6) or required
reintervention (n=35). In 1 of these patients, reintervention
was followed by death. Death or reintervention was more
common in patients with new, significant, and/or progressive
RVOT obstruction (69% versus 33%; P=0.042) and was lower
(P=0.015) in streptococcal IE (30%) than in staphylococcal
(72%) and Gram-negative bacterial (73%) IE. On multivariate
regression analysis, nonstreptococcal IE was an independent
predictor of death/reintervention (odds ratio, 4.28; 95% CI,
1.16–15.78; P=0.029).
Discussion
Clinical trials have shown the safety and efficacy of TPVI, with
excellent short-term outcomes2 and freedom from reinter-
vention in most patients up to 5 years.3 However, the risk of
IE of the Melody valve is increasingly recognized as a
significant threat to the long-term valve function.
Although IE is associated with high mortality and severe
complications,12 its management is mostly based on expert
opinion rather than on evidence.12 Shortage of evidence is
basically because of the low incidence of the disease and the
scarcity of randomized trials and meta-analyses.12 Original
studies are, definitely, more robust than inferences from
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Data are given as meanSD unless otherwise indicated. AS indicates aortic stenosis;
IE, infective endocarditis; HACEK, Haemophilus parainfluenzae, H. aphrophilus,
H. paraphrophilus, H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium
hominis, Eikenella corrodens, Kingella kingae, and K. denitrificans; PG, pressure gradient;
PR, pulmonary regurgitation; RVOT, right ventricular outflow tract; S/P, status post; TA,
truncus arteriosus; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TPVI,
transcatheter pulmonary valve implantation.
*From 22 reports published between 2011 and 2017.17–38
†Corynebacterium pseudodiphtheriticum in 3 cases and Corynebacterium striatum in
1 case.
‡Haemophilus influenzae in 1 case and Haemophilus parainfluenzae in another case.
§In 3 cases, serologic findings and polymerase chain reaction of excised valves revealed
Bartonella henselae.
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 8
































 http://ahajournals.org by on A
ugust 14, 2019
reviews/meta-analyses but only when original studies are
adequately powered. Given the fact that IE is a relatively
uncommon disease, frequently occurring long after the index
procedure, and is challenging to diagnose in many instances,
data from individual registries are often inadequate to derive
evidence on the natural history and the management of IE.
Because more and more reports from small single-center
registries are reporting an extraordinarily high IE risk with the
Melody valve, we conducted this systematic review. Although
desirable in the field of congenital heart diseases, in which
studies are usually small scale, meta-analysis of observational
studies with differences in baseline characteristics and
anatomic substrates, procedural characteristics, and follow-
up durations might introduce imprecision into the results,
even when proper statistical methods are applied. Therefore,
we opted to pool patient-level data, whereas study-level data
were systematically reviewed without pooling.
Risk of IE After Melody Valve Implantation
The data provided in the present review highlight that only
large, well-designed, prospective studies will be able to assess
the actual rate and the potential risk factors for IE after TPVI.
The phenomenon of reporting higher rates of IE in the later
than the earlier studies (Figure 3) can be in part because of the
increasing awareness of the risk of IE that led to a more careful
surveillance and is in line with a global trend toward an
increased incidence of IE.39 We found that early postimplan-
tation Melody valve endocarditis is uncommon, that only one
third (32%) of cases occur within the first year after TPVI, and
that the risk persists thereafter, with 23% of cases developing
beyond 3 years after the procedure. This comes in agreement
with the findings of a large contemporary study of patients with
adult congenital heart disease (n=14 224 patients),40 in whom
the presence of valve-containing prostheticswas independently
associated with greater risk of IE that persists in the long-term
(hazard ratio of IE beyond 12 months after prosthesis implan-
tation, 5.3; 95% CI, 3.5–7.9). The authors suggested that this
reflects the fact that the risk is likely not attributable only to
surgical factors associated with implantation but also to the
mere long-term presence of those prostheses.40
Patient- Versus Device-Related Vulnerability to IE
We found that in many patients with Melody valve IE, an
identifiable portal of bacteria was present and most frequently
Figure 4. A cumulative curve of the individual patients with Melody valve endocarditis displaying (on the
horizontal axis) the time interval between transcatheter pulmonary valve implantation (TPVI) and the onset
of infective endocarditis (IE). The figure represents data from 59 (of 69) patients in whom the exact time
interval from TPVI to IE was reported.
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 9
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involved an unprotected dental procedure/orthodontic/oral
trauma. This highlights the importance of pre-TPVI counseling
(including a meticulous dental review) and continuous edu-
cation of patients and families to lower the exposure to
portals of infection, as well as the necessity of routine
antibiotic prophylaxis before any invasive maneuver. Notwith-
standing, patients with Melody valve implantation combine 2
conditions predisposing to a higher rate of IE and a higher
risk of adverse outcome from endocarditis: the use of a
prosthetic cardiac valve in the setting of a repaired complex
congenital heart disease and an unfavorable hemodynamic
environment in the vicinity of that prosthesis (which could
interfere with complete prosthesis endothelialization).41 The
most recent US and European guidelines on the management
of valvular heart diseases recommend antibiotic prophylaxis
before dental procedures in patients with prosthetic cardiac
valves, including transcatheter-implanted prostheses.42,43
Although some clinical guidelines, on the other hand, advise
against routine antibiotic prophylaxis against IE even in
patients with a high risk of acquiring IE and of having a worse
outcome of IE, there have been some signals indicting this
conservative antibiotic prophylaxis approach for a trend of
IE rates to increase.39,44 Our data give an example of a
condition and a patient population with an exceptionally
significant rate of IE, with many of the episodes being linked
to dental procedures.
In addition to patient-related risk factors (eg, older age,26
male sex,26 history of IE,17 discontinuation of antiplatelets,29
and exposure to unprotected medical procedure29) and
procedure-related risk factors (eg, longer procedure,26 higher
number of stents,26 and higher residual RVOT gradient14),
some inherent device characteristics have been indicated by
histopathologic studies as risk factors predisposing to IE. A
selective propensity of bovine jugular tissue (the precursor of
the Melody valve leaflets) to histological lesions during
procedural steps45 and to bacterial adherence46 was shown
in in-vitro studies, especially after procedural manipulation-
induced leaflet damage.46 These findings are in line with the
observed higher propensity of valves with bovine jugular vein
leaflets (Melody valve and Contegra graft) to IE than
pulmonary homografts.18,19,47 The risk of IE after TPVI with
the Sapien valve (Edwards Lifesciences, Irvine, CA), which has
bovine pericardial tissue leaflets, albeit still present,48 seems
to be lower than with the Melody valve.20,22,49 However, the
number of implanted Sapien valves in the pulmonary position
and the duration of follow-up are far lower than those of the
Melody valve, and this might lead to underestimating the
incidence of IE in Sapien valves.
In another study of explanted infected Melody valves,50
pathologic examination revealed the presence of granulocytes
in the preexisting surgical conduit in all cases, denoting that
the space between the Melody valve stent and the underlying
conduit with little neovascularization might represent a
blind spot that cannot be reached by antibiotics. This blind
spot seems to harbor the microorganism leading to failure of
antibiotics to eradicate the infection. This is further sup-
ported by the association between a higher number of stents
in the RVOT and the risk of Melody valve IE reported in 1
study.25
In the same study,50 a thrombotic material was found at the
basis of the leaflets or at the graft wall in most cases. Turbulent
blood flow in the RVOT might lead to endothelial damage
predisposing to nonbacterial thrombotic endocarditis that can
turn infective after any transient bacteremia.5 These findings
further support the association between discontinuation of
antiplatelets and the development of endocarditis reported in 1
study.28 Data from transcatheter aortic valve replacement
(TAVR) studies refer to a significant risk of clinical/subclinical
leaflet thrombosis that can be prevented and effectively treated
by oral anticoagulation.51,52 It is, however, unknown whether
the same phenomenon is relevant to TPVI. Notwithstanding,
more rigorous use of multislice computed tomography (MSCT)
in post-TPVI surveillance (especially in cases with increasing
RVOT pressure) might provide more insights into the actual
incidence of hypoattenuated leaflet thickening after TPVI and its
clinical significance.
Risk of IE After Transcatheter Versus Surgical
Pulmonary Valve Replacement
In a large series (n=586 patients) reported by Mery et al,47
including a total of 792 valved pulmonary conduits, 23
conduits (2.9%) developed endocarditis at a median of 5 years
(range, 19 days to 11 years) after surgery. Bovine jugular
grafts were associated with a significantly greater risk of late
endocarditis (hazard ratio, 9.05; 95% CI, 2.6–31.8 compared
with homografts).47 None of the patients with endocarditis
died of related causes, and 16 (70%) of infected conduits were
surgically replaced. In another study by Van Dijck et al,19
Melody valves, homografts, and Contegra grafts were com-
pared for the incidence of IE. The annualized rate of IE was
>3-fold higher after Melody valve implantation (3.0%; 95% CI,
1.3%–5.8% per patient-year) than after homograft implanta-
tion (0.8%; 95% CI, 0.4%–1.3% per patient-year), whereas it
was 2.4% (95% CI, 1.0%–3.8%) per patient-year in the
Contegra group. In a recent meta-analysis of 50 studies
involving 7063 patients, bovine jugular vein valves, indepen-
dent of implantation technique, were associated with a higher
cumulative risk of IE compared with other types of right
ventricle-to-pulmonary artery conduits (median cumulative
incidence, 5.4% versus 1.2%; P<0.0001). There was no
difference in the incidence of endocarditis between cathe-
ter-based and surgically implanted bovine valves, suggesting
that the substrate for infection is related to the tissue
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 10
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precursor of the valve.8 However, this meta-analysis is
limited by reporting the incidence of endocarditis, which is
a time-dependent event, in terms of a crude cumulative
incidence.53
Risk of IE After Transcatheter Pulmonary Valve
Replacement Versus TAVR
In a large study by Regueiro et al54 that included 20 006
patients with TAVR, 250 had definite IE (incidence, 1.1%; 95%
CI, 1.1%–1.4% per patient-year) at a median interval of
5.3 months (interquartile range, 1.5–13.4 months) after the
procedure, and IE was early in 178 patients (71.2%). In-
hospital mortality and surgical conversion rates were 36% and
15%, respectively. In a pooled analysis of multiple studies, IE
developed at 241287 days after TAVR, 28% of patients
required a surgical intervention, and 30-day mortality was
22%.55 These studies, and others,56–58 highlight that IE seems
to be remarkably less common and to occur earlier after TAVR
than after transcatheter pulmonary valve replacement.
Microbiologic Features and Outcomes of Melody
Valve IE
We found that post-TPVI endocarditis involves staphylococci
(42%) or streptococci (30%) in most cases. This comes in line
with the overall microbiologic profile of IE in adults (staphylo-
cocci, 42%; and streptococci, 29%)59 and in pediatrics (staphy-
lococci, 43%; and streptococci, 40%).60 Similar patterns were
also reported in prosthetic valve endocarditis (PVE; staphylo-
cocci, 40%; and streptococci, 22%)59 and in pulmonary surgical
conduit IE (staphylococci, 53%; and streptococci, 43%).47
Accordingly, it can be suggested that initial empirical antibiotic
therapy in cases with suspected Melody valve IE should follow a
similar protocol to that of PVE, which specifically targets the
virulent Staphylococcus aureus.12 This microorganism was
shown in the present study to be the single most common
organism involved inMelody valve IE and to be associatedwith a
worse outcome than streptococcal infection.
We found that Melody valve IE leads to reintervention in
52% of cases and death in 8.7% of cases, compared with a
65% to 70% rate of surgical reintervention35,47 and a mortality
rate of 13%16,35 in the setting of pulmonary surgical conduit
IE. This comparison emphasizes that although the rate of IE
is generally lower in pulmonary surgical conduits than after
TPVI, IE-related morbidity and mortality risks might be
higher.
We found that streptococcal infection and the lack of RVOT
obstruction are associated with a significantly better out-
come. A similar association between streptococcal involve-
ment and the freedom from in-hospital death was previously
reported in adults with IE.59 It turns out that these 2 criteria
(the type of the organism and the presence/absence of RVOT
obstruction) can be used for risk stratification of patients
presenting with Melody valve IE.
Diagnostic Criteria
In the initial phase of TPVI experience, reobstruction of the
RVOT with subsequent reintervention was relatively common,
and it was mostly attributable to stent fracture.3 In the more
contemporary TPVI experience, with the adoption of routine
prestenting, reintervention attributable to recurrent valve
obstruction became uncommon.4,24,61,62 In the present
review, a strong association between IE and Melody valve
obstructive dysfunction was obviated. The direction of
causality of this relationship (IE leading to valve obstruction
versus valve dysfunction predisposing to IE) is not easy to
conclude on. Notwithstanding, in some reports,22,30,31,36 in-
hospital serial Doppler studies have documented a progres-
sive pressure gradient increase during the course of IE. RVOT
obstruction was the reason for most reinterventions, and
whether pressure increase can be, in part, attributable to
leaflet thrombosis and can be resolved by anticoagulation
treatment without reintervention is still an open question.
Although considered by Duke criteria as a sign of valve
involvement in IE, new valve regurgitation was reported in only
2 of 69 cases. Histopathologic studies have confirmed the
same finding,50 as have other reports,14,19 concluding that
insufficiency is a rare manifestation of Melody valve IE.
It is well acknowledged that echocardiography, especially
transthoracic echocardiography (TTE), affords only modest
sensitivity (50%) for the detection of vegetations in PVE.12 In
the setting of IE after Melody valve implantation, echocardio-
graphic detection of vegetations is limited to only one third of
published case reports, likely because of the anterior position
of the RVOT and artefacts from the prosthetic valve stent and
the underlying, mostly degenerated calcified, conduit. Some
relevant points of clinical importance are worth mentioning:
First, failure to visualize vegetations using cardiac imaging
does not exclude their presence, because they can still be
visualized intraoperatively18,22 or on autopsy27 in cases with
initially negative imaging studies. Second, unlike classic left-
sided PVE, where transesophageal echocardiography (TEE) is
superior to TTE in detecting vegetations, TEE does not always
have an added value to TTE results in transcatheter and
surgical prosthetic pulmonary valve endocarditis.21,23,33,35,38
Diagnostic accuracy of TEE can be improved using biplane
imaging63 and by using dedicated acquisition views64 (eg, high
esophageal interrogation of the distal valve stent). A system-
atic combination of TTE and TEE35 was suggested to improve
diagnostic accuracy, compared with either modality used
alone. In some studies,21,23,38 intracardiac echocardiography
was successful in detecting vegetations missed by TTE/TEE.
DOI: 10.1161/JAHA.117.008163 Journal of the American Heart Association 11
































 http://ahajournals.org by on A
ugust 14, 2019
Third, other imaging tools (eg, MSCT29 and PET scan28) can
detect vegetations missed by echocardiography.
The combination ofMSCTwith PET has been shown to have an
added value over TTE/TEE in confirming PVE,65,66 especially in
patients with negative or doubtful echocardiographic results.67
On the basis of these data, the latest guidelines on the
management of IE12 considered an abnormal activity around
the site of the prosthetic valve detected on PET/MSCT as a
“major criterion” of IE. There are few, but rather encouraging,
reports on thesuccessofPET/MSCT toprovide a goodalternative
to echocardiography in IE after Melody valve implantation.28,29
It turns out that the classic approach recommended by the
practice guidelines12 to confirm valvular involvement in the
setting of PVE (ie, detection of vegetation[s] and/or [para-]
prosthetic regurgitation by TTE/TEE) is inefficient in a large
proportion of patients with Melody valve IE. This observation
calls for amodified diagnostic approach in these cases, possibly
including progressive RVOT obstruction and abnormal activity
on MSCT/PET as important additional diagnostic criteria.
Finally, given the aforementioned diagnostic challenges,
pathologic examination of tissue samples that are excised
during surgery should be routinely applied. This histological
examination of resected valvular tissue is considered
by the guidelines12 as “the gold standard” for the
diagnosis of IE.
Limitations
This review, although intended to be comprehensive, still
bears the limitations inherent to a retrospective review of
published data (eg, selection bias of patients with a relatively
better outcome). In general, comparisons between patients
with versus without IE were either missing or, when present,
significantly heterogeneous and seriously limited by the small
number in either/both groups, precluding appropriateness for
pooled analysis.
Conclusions and Clinical Implications
The risk of IE after implantation of a Melody valve is
significant, at least over the first 3 years after TPVI, with few
cases occurring in the early postprocedural period. However,
the reported incidence varies considerably between the
studies. Diagnosis is challenging, especially in terms of the
documentation of valvular involvement in the infective
process. The classic modified Duke criteria, which heavily
rely on echocardiographic signs, show a modest diagnostic
yield in post-TPVI endocarditis. Approximately 52% of patients
require reintervention, either surgically or percutaneously,
with the infection being controllable with antibiotics in some
cases, especially when streptococci are involved and the
RVOT is not obstructed.
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Data S1.
PubMed search terms: 
(("Endocarditis"[Mesh] OR "Endocarditis"[tiab] OR infection[Mesh]) AND ( "Heart Valve 
Prosthesis"[Mesh] OR "Heart Valve Prosthesis Implantation"[Mesh] OR melody valve[tiab]) 
AND (pulmonary valve[Mesh] OR pulmonary valve[tiab] OR right ventricular outflow[tiab])) 
OR (("endocarditis"[Mesh] OR "endocardit*"[tiab]) AND (Melody[tiab] OR transcatheter 




 http://ahajournals.org by on A
ugust 14, 2019




 http://ahajournals.org by on A
ugust 14, 2019
